促黄体生成素释放激素激动剂（ICI 118630，诺雷德）在绝经前晚期乳腺癌中的应用。
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
作者信息
Williams M R, Walker K J, Turkes A, Blamey R W, Nicholson R I
出版信息
Br J Cancer. 1986 May;53(5):629-36. doi: 10.1038/bjc.1986.106.
Abstract
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
摘要
53例绝经前晚期乳腺癌患者在一项I期临床试验中接受了一种强效新型促黄体生成激素释放激素激动剂诺雷德（ICI 118630）治疗。疾病进展后，26例患者接受了治疗性卵巢切除术。我们报告了45例可评估患者的临床和内分泌治疗反应。该系列中诺雷德的反应率为31%，原发肿瘤的雌激素受体（ER）状态可预测对促黄体生成激素释放激素的反应。
相似文献
1
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.促黄体生成素释放激素激动剂（ICI 118630，诺雷德）在绝经前晚期乳腺癌中的应用。
Br J Cancer. 1986 May;53(5):629-36. doi: 10.1038/bjc.1986.106.
2
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.戈舍瑞林，一种长效促性腺激素释放激素激动剂，用于治疗绝经前转移性乳腺癌患者。德国诺雷德试验组。
J Clin Oncol. 1989 Aug;7(8):1113-9. doi: 10.1200/JCO.1989.7.8.1113.
3
LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
Eur J Gynaecol Oncol. 1991;12(6):429-37.
4
Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
J Endocrinol. 1986 Nov;111(2):349-53. doi: 10.1677/joe.0.1110349.
5
Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
J Steroid Biochem. 1985 Nov;23(5B):843-7. doi: 10.1016/s0022-4731(85)80025-x.
6
Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
Tumori. 1991 Apr 30;77(2):145-50. doi: 10.1177/030089169107700211.
7
Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Anticancer Drugs. 1992 Feb;3(1):3-8. doi: 10.1097/00001813-199202000-00001.
8
Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
Eur J Cancer Clin Oncol. 1989 Apr;25(4):651-4. doi: 10.1016/0277-5379(89)90200-9.
9
Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
Fertil Steril. 1988 Jan;49(1):163-5. doi: 10.1016/s0015-0282(16)59670-8.
10
[Zoladex as a depot GnRH agonist in premenopausal metastatic breast cancer].
Arch Gynecol Obstet. 1989;245(1-4):741-3. doi: 10.1007/BF02417537.
引用本文的文献
1
Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.靶向雌激素受体信号传导在乳腺癌治疗中的应用
Adv Exp Med Biol. 2025;1464:449-474. doi: 10.1007/978-3-031-70875-6_22.
2
Hormonal Therapies in Cancers.癌症的激素治疗。
Cancer Treat Res. 2023;185:91-104. doi: 10.1007/978-3-031-27156-4_6.
3
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.戈舍瑞林联合阿那曲唑作为绝经前晚期乳腺癌二线内分泌治疗的临床及内分泌学数据。
Br J Cancer. 2004 Feb 9;90(3):590-4. doi: 10.1038/sj.bjc.6601557.
4
Clinical pharmacokinetics of goserelin.戈舍瑞林的临床药代动力学
Clin Pharmacokinet. 2000 Jul;39(1):27-48. doi: 10.2165/00003088-200039010-00003.
5
Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts.抗促性腺激素释放激素抗体可抑制MCF7人乳腺癌异种移植瘤的生长。
Br J Cancer. 1999 May;80(3-4):352-9. doi: 10.1038/sj.bjc.6690362.
6
Transdermal iontophoresis. Pharmacokinetic considerations.
Clin Pharmacokinet. 1994 May;26(5):327-34. doi: 10.2165/00003088-199426050-00001.
7
Clinical applications of GnRH analogs.促性腺激素释放激素类似物的临床应用。
J Endocrinol Invest. 1988 Nov;11(10):745-54. doi: 10.1007/BF03350939.
8
Gonadotrophin hormone releasing analogues open new doors in cancer treatment.促性腺激素释放类似物为癌症治疗打开了新的大门。
Br Med J (Clin Res Ed). 1987 Oct 31;295(6606):1084-5. doi: 10.1136/bmj.295.6606.1084.
9
Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.促黄体生成激素释放激素及其类似物：生物学特性与临床应用综述
J Endocrinol Invest. 1988 Jul-Aug;11(7):535-57. doi: 10.1007/BF03350179.
10
Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.戈舍瑞林（诺雷德）用于绝经前晚期乳腺癌：缓解持续时间和生存期
Br J Cancer. 1990 Nov;62(5):868-70. doi: 10.1038/bjc.1990.397.
本文引用的文献
1
THERAPEUTIC CASTRATION VERSUS PROPHYLACTIC CASTRATION IN BREAST CANCER.
Surg Gynecol Obstet. 1964 Mar;118:524-40.
2
From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.从避孕到癌症：促黄体生成素释放激素类似物作为抗肿瘤药物的治疗应用综述
Yale J Biol Med. 1982 Jan-Feb;55(1):27-47.
3
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.在转移性乳腺癌中，长期使用促黄体激素释放激素（LHRH）激动剂进行单一治疗以及与其他辅助内分泌治疗联合使用。
Med Oncol Tumor Pharmacother. 1984;1(2):123-8. doi: 10.1007/BF02934984.
4
Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.晚期乳腺癌治疗反应评估：瑞士日内瓦国际抗癌联盟临床肿瘤学项目。
Cancer. 1977 Mar;39(3):1289-94. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f.
5
Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.一系列高剂量新型促黄体生成激素释放激素类似物对未切除卵巢雌性大鼠的影响。
Br J Cancer. 1979 Mar;39(3):274-9. doi: 10.1038/bjc.1979.51.
6
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.新型强效促黄体生成素释放激素激动剂ICI 118630的抗肿瘤活性
Br J Cancer. 1979 Mar;39(3):268-73. doi: 10.1038/bjc.1979.50.
Zotero 插件